Recent studies have highlighted the dysregulated transcriptome and signaling pathways that underpin the aberrant biology, aggressive phenotype, and refractoriness to standard therapy of EVI1-overexpressing myeloid malignancies (Fig. 5). This evidence concerns the gene RUNX1 and myeloid neoplasm.